Galapagos NV Receives Transparency Notification
Recently, Galapagos NV (Euronext & NASDAQ: GLPG) announced that it has received a transparency notification along with a 13D filing from Tang Capital. This marks an important milestone for the company, indicating a significant shareholding position held by Tang Capital.
Details of the Notification
On February 14, 2025, Galapagos was notified on behalf of Mr. Kevin Tang and various entities under Tang Capital Management, LLC. These entities have reported holding a combined total of 887,227 ordinary shares, as well as 2,436,180 American Depositary Receipts (ADRs). Each ADR corresponds to one ordinary share, which together contribute to 3,323,407 voting rights for Galapagos, representing approximately 5.04% of the company's total outstanding shares.
Voting Rights and Management Powers
The notification sheds light on the management structure within Tang Capital. It highlights how Mr. Tang, alongside other Tang Capital groups, shares voting and dispositive powers over the shares held. Notably, they have the freedom to exercise voting rights at their discretion without specific instructions. This collaborative governance indicates a unified approach towards managing their significant stake in Galapagos.
Filing of Schedule 13D
Alongside the transparency notification, Tang Capital also filed a Schedule 13D with the SEC on the same day. This filing revealed that Tang Capital beneficially owns 4,910,525 voting rights. It consists of 966,119 ordinary shares and 2,544,406 ADRs. Moreover, Tang Capital holds 1,400,000 ADRs associated with call options on Galapagos shares that are set to expire on February 21, 2025.
Potential Share Obligations
The Schedule 13D filing also discussed additional significant obligations related to Galapagos shares. It mentioned potential obligations to purchase 1,043,500 shares through put options and to sell 200,000 shares via call options, further enhancing the profile of Tang Capital as a substantial player in the company's equity structure.
Company Overview
Galapagos NV is a forward-thinking biotechnology company dedicated to improving patient health outcomes through scientific advancement and innovation. With a robust pipeline of therapies addressing substantial unmet medical needs, Galapagos combines cutting-edge technology with collaborative efforts to drive results. The company’s operations are rooted in both Europe and the U.S., showcasing its commitment to comprehensive healthcare solutions.
A Commitment to Innovation
Galapagos aims not only to meet current medical challenges but also to set the stage for the future of healthcare. Their strategies include a focus on personalized medicine and innovative treatment approaches that emphasize quality of life. This commitment to life-changing science assures stakeholders that Galapagos is genuinely invested in the health and well-being of patients worldwide.
Contact Information
To inquire further about Galapagos NV, interested parties can reach out to:
Media Inquiries:
Srikant Ramaswami
Phone: +1 412 699 0359
Marieke Vermeersch
Phone: +32 479 490 603
Email: media@glpg.com
Investor Inquiries:
Srikant Ramaswami
Phone: +1 412 699 0359
Sandra Cauwenberghs
Phone: +32 495 58 46 63
Email: ir@glpg.com
Frequently Asked Questions
What is the recent notification received by Galapagos NV?
Galapagos NV received a transparency notification and a Schedule 13D filing from Tang Capital, indicating a significant shareholding.
Who is behind Tang Capital?
Tang Capital is led by Mr. Kevin Tang, who is involved in the management and decision-making regarding the shares held.
How much of Galapagos' shares does Tang Capital own?
Tang Capital owns approximately 5.04% of Galapagos' outstanding shares, as outlined in the transparency notification.
What does the Schedule 13D filing indicate?
The Schedule 13D filing shows that Tang Capital beneficially owns 4,910,525 voting rights, along with potential obligations related to share options.
What is Galapagos NV's mission?
Galapagos NV focuses on transforming patient outcomes through innovative solutions, targeting high unmet medical needs in biotechnology.
